IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Immunotherapy: A New Standard of Care in NSCLC
May 15, 2017 | Online


Cancer immunotherapy is emerging as one of the most promising areas of cancer research and treatment. Overall, the goal of cancer immunotherapy is to stimulate a patient's immune system to recognize cancer cells as foreign and attack them. Data from recent phase III trials established immunotherapy as the new standard of care as first-line therapy in selected patients with non-small cell lung cancer (NSCLC) and irrespective of PD-L1 expression in second-line setting.  The aim of this webinar is to present the most recent data on checkpoint inhibitors and how this innovative approach is changing the paradigm for NSCLC therapy.

Accordingly, in this program we will:
  • illustrate how immunotherapy is changing the algorithm of NSCLC therapy;
  • address how to select appropriate patients for immunotherapy;
  • examine the future development of immunotherapy in NSCLC.

What you should expect to learn

After viewing this program, attendees will:

  • recognize the current role of immunotherapy in the first-line and second-line treatment of advanced stage NSCLC;
  • apply selection criteria to identify patients most likely to benefit from immunotherapy;
  • recognize the major clinical trials underway to further develop the utility of immune checkpoint inhibitors.

Federico Cappuzzo, MD

Director of Medical Oncology
Department of Oncology and Hematology
Ospedale Santa Maria delle Croci
Ravenna, Italy



Pr Françoise Mornex, MD, PhD
Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France